Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ximelagatran (H 376-95), a direct thrombin inhibitor, can be taken orally and acts solely by inhibiting the actions of thrombin. Ximelagatran is converted to the active agent melagatran in vivo.
説明 | Ximelagatran (H 376-95), a direct thrombin inhibitor, can be taken orally and acts solely by inhibiting the actions of thrombin. Ximelagatran is converted to the active agent melagatran in vivo. |
In vitro | Ximelagatran, an orally administered direct thrombin inhibitor, is currently being developed for both the prophylaxis and treatment of thromboembolism. Once ingested, it is rapidly absorbed and converted into its active metabolite, Melagatran, which acts as a reversible, active-site inhibitor targeting both free and clot-bound thrombin, showcasing stable and reproducible pharmacokinetic properties. Initial research indicates Ximelagatran's promising efficacy and safety profile in preventing venous thromboembolism following total knee or hip replacement surgeries[1]. |
別名 | EXANTA, H 376-95, H37695, H 376/95, H-37695, H 37695 |
分子量 | 473.57 |
分子式 | C24H35N5O5 |
CAS No. | 192939-46-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/ml (116.14 mM)
H2O: Insoluble
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ximelagatran 192939-46-1 Proteases/Proteasome Thrombin EXANTA H 376-95 Inhibitor inhibit H37695 H 376/95 H-37695 H 37695 inhibitor